Arcturus Therapeutics Holdings (ARCT) EBT Margin (2018 - 2026)
Arcturus Therapeutics Holdings (ARCT) posted EBT Margin of 2746.87% for Q1 2026, down 579.66% on a QoQ basis from 404.16% in Q4 2025, and down 269896.0% year-over-year from N/an in Q1 2025.
Arcturus Therapeutics Holdings (ARCT) EBT Margin (2018 - 2026) Analysis & Trends
Arcturus Therapeutics Holdings' EBT Margin history runs 9 years deep, the most recent figure standing at 2746.87% for Q1 2026.
- Quarterly EBT Margin fell 269896.0% year-over-year to 2746.87% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 197.99% (down 15027.0% YoY) and the FY2025 annual result came in at 80.19%, down 2705.0% from the prior year.
- EBT Margin was 2746.87% for Q1 2026 at Arcturus Therapeutics Holdings, down from 404.16% in the prior quarter.
- Across five years, EBT Margin topped out at 74.02% in Q4 2022 and bottomed at 2746.87% in Q1 2026.
- A 5-year average of 312.35% and a median of 69.58% in 2024 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2022 — EBT Margin soared 300312 bps — and 2026, when it plunged 269896 bps.
- Arcturus Therapeutics Holdings' EBT Margin stood at 74.02% in 2022, then plunged by 150 bps to 37.09% in 2023, then sank by 255 bps to 131.81% in 2024, then tumbled by 207 bps to 404.16% in 2025, then slumped by 580 bps to 2746.87% in 2026.
- Business Quant data shows ARCT's EBT Margin at 2746.87% in Q1 2026, 404.16% in Q4 2025, and 78.41% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Arcturus Therapeutics Holdings | 164.57 Mn | -46.81 Mn | - | -2,746.87% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,746.87% |
| Dec 31, 2025 | -404.16% |
| Sep 30, 2025 | -78.41% |
| Jun 30, 2025 | -32.42% |
| Mar 31, 2025 | -47.91% |
| Dec 31, 2024 | -131.81% |
| Sep 30, 2024 | -17.09% |
| Jun 30, 2024 | -34.83% |
| Mar 31, 2024 | -69.58% |
| Dec 31, 2023 | -37.09% |
| Sep 30, 2023 | -33.96% |
| Jun 30, 2023 | -494.09% |
| Mar 31, 2023 | 63.35% |
| Dec 31, 2022 | 74.02% |
| Sep 30, 2022 | -263.79% |
| Jun 30, 2022 | -79.59% |
| Mar 31, 2022 | -975.76% |
| Dec 31, 2021 | -652.66% |
| Sep 30, 2021 | -2,514.40% |
| Jun 30, 2021 | -3,082.71% |